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Abstract
Significant advances in our understanding of RA and its management have been made in the past decade,
resulting in earlier intervention with biologic DMARDs, particularly in patients with evidence of aggressive,
erosive disease. Here, one such biologic therapy, the T-cell co-stimulation modulator abatacept, is dis-
cussed, exploring clinical evidence published to date on its use in patients with very early arthritis/early RA
who are MTX naı ¨ve, and in patients with established RA and an inadequate response to MTX or TNF
antagonists. Data from relevant clinical trials are overviewed, discussing the clinical efficacy of abatacept
in early disease, the clinical outcomes over long-term treatment in different patient populations and the
effects of abatacept on structural damage. Findings from integrated safety analyses of abatacept clinical
trial data, representing 10366 patient-years of exposure are described, and clinically important safety
events, including serious infections, malignancies and autoimmune events, are highlighted. It is concluded
that abatacept represents an effective treatment option with an established safety profile across different
patient populations, including patients with both early and erosive RA and those with established disease.
Furthermore, efficacy data from studies in patients with early disease suggest that the risk–benefit profile
of abatacept may be more favourable when introduced earlier in the treatment paradigm.
Key words: Rheumatoid arthritis, Biological therapies, Clinical trials, Abatacept.
Introduction
Significant advances in our understanding of RA and its
management have demonstrated that early intervention,
particularly in patients with evidence of aggressive,
erosive disease, can prevent the irreversible structural
damage characteristic of RA. The benefit observed is
often optimized when combination treatment with both
traditional and biologic DMARDs is administered [1–6].
Clinical practice guidelines recommend that the majority
of patients should start treatment with a conventional
DMARD, and in cases of treatment failure a biologic
should be added; however, combination therapy should
be considered early in DMARD-naı ¨ve patients if they pre-
sent with poor prognostic factors, such as erosion, posi-
tivity for anti-CCP or RF and high disease activity [7].
Progress towards a framework for identifying patients
with early disease who are at high risk of developing ero-
sive and progressive RA—and thus would benefit from
early DMARD intervention—has been made in the form
of joint guidelines from the EULAR and the ACR [8], and
guidelines from the strate ´gie the ´rapeutique de la polyar-
thrite (therapeutic strategies in RA) working group of the
French Society of Rheumatology (study and follow-up of
undifferentiated early arthritis). The latter specifically rec-
ommend very early use (46 months from diagnosis) of
biologics in patients with poor prognostic factors [9].
However, one needs to take into account the benefit–
risk profile of the therapeutic options available when con-
sidering this course of action [10].
Biologic DMARDs, including the TNF antagonists—
infliximab, etanercept, adalimumab, golimumab and
certolizumab—the B-cell depleter rituximab, the IL-6
receptor antagonist tocilizumab and the T-cell co-
stimulation modulator abatacept, have demonstrated
clinical efficacy and radiographic benefit in patients with
moderate-to-severe RA who have demonstrated an inad-
equate response to at least one non-biologic DMARD [11–
18]. Furthermore, efficacy benefits have been seen with
some biologics in patients with severe, active and pro-
gressive early disease not previously treated with
conventional DMARDs [19–23].
This review will focus on one of these biologic agents,
abatacept, and the clinical experience to date examining
intervention in various patient populations, including
those with very early arthritis/early RA who are MTX naı ¨ve
[23, 24], and in patients with established RA and an inad-
equate response to MTX [25, 26] or TNF antagonists [27].
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Abatacept is a selective co-stimulation modulator that in-
hibits T-cell activation by binding to CD80/86, and mod-
ulating its interaction with CD28 [28]—a co-stimulatory
signal necessary for the full activation of T cells.
Activated T cells are implicated in the pathogenesis of
RA via amplification of the inflammatory cascade that
leads to joint inflammation and destruction in RA [29,
30]. The effect of abatacept on the inflammatory cascade
has been demonstrated by quantitative PCR studies and
evaluation of synovial biopsies in patients with active
RA who had previously failed TNF antagonist therapy.
Findings from these studies demonstrate a reduction in
expression of most inflammatory genes, and a small,
largely non-significant reduction in cellular content follow-
ing abatacept treatment; this suggests that abatacept re-
duces the inflammatory status of the synovium without
disrupting cellular homoeostasis [31]. These observations
are supported by clinical trial data, which have demon-
strated a reduction in serum levels of inflammatory bio-
markers to within ‘normal’ levels following abatacept
treatment, implying that abatacept may help to normalize
the levels of downstream inflammatory mediators. The
unique mechanism of action of abatacept may offer
significant therapeutic benefit to patients by specifically
addressing the underlying RA pathophysiology [32].
Overview of abatacept clinical
experience
Early disease
Abatacept study to gauge remission and joint damage
progression in MTX-naı ¨ve patients with early erosive RA
The 2-year abatacept study to gauge remission and joint
damage progression in MTX-naı ¨ve patients with early ero-
sive RA (AGREE) study consisted of a 12-month double-
blind (DB) period followed by a 12-month open-label
period in MTX-naı ¨ve patients with early RA [23]. Patients
had poor prognostic factors that are highly predictive of
an aggressive disease course, including high CRP levels,
radiographic evidence of erosions and seropositivity for
RF or anti-CCP2. Patients were randomized 1:1 to re-
ceive abatacept (approved dose [33]) plus MTX (n=256)
or MTX alone (n=253) [23]. All patients received open-
label abatacept plus MTX from Year 1 onwards. The
co-primary endpoints were 28-joint DAS (DAS-28)-defined
remission and joint damage progression [Genant-modified
[34] total score (TS)] at Year 1. At baseline, patients
had short disease duration and high disease activity
(Table 1).
At Year 1, significantly more patients treated with aba-
tacept plus MTX achieved DAS-28 (CRP)-defined remis-
sion and ACR50 and ACR70 responses (Table 2), and the
difference between treatment arms was significant by
Month 2. Over 1 year, 27.3 vs 11.9% of abatacept plus
MTX- vs MTX alone-treated patients (P<0.001) achieved
a major clinical response (ACR70 maintained for 56 con-
secutive months) [23]. Significant improvements were also
seen in physical function at Year 1, for abatacept plus
MTX- vs MTX alone-treated patients [23]. In addition, aba-
tacept plus MTX demonstrated a higher likelihood of
increasing or maintaining initial improvements in ACR re-
sponses and physical function over 1 year than MTX alone
in patient-level post hoc analyses [35].
Improvements in disease activity and ACR responses
were sustained or improved over the second year for pa-
tients remaining on abatacept plus MTX therapy, with
55.2% achieving remission at Year 2 [36]. After patients
randomized to MTX alone were initiated on abatacept plus
MTX at Year 1, improvements in these efficacy endpoints
were seen, with 44.5% in remission at Year 2, increased
from 26.9% at Year 1 [36].
Changes from baseline to Year 1 in Genant-modified
Sharp TS and erosion score (ES) were significantly lower
for MTX-naı ¨ve patients randomized to abatacept plus
MTX vs MTX alone (Fig. 1A) [23]. Furthermore, there was
an increasing degree of inhibition of progression in Year 2
relative to Year 1 for patients originally randomized
to abatacept [37]. For patients originally receiving
MTX alone, structural damage progression was reduced
over Year 2 relative to Year 1, following the addition of
abatacept [37]. However, overall structural damage pro-
gression at Year 2 remained greater for these patients
compared with patients who received abatacept from
baseline [37].
Abatacept study to determine the effectiveness in
preventing the development of RA in patients with
undifferentiated inflammatory arthritis and to evaluate
safety and tolerability
The potential for early treatment with abatacept to delay
the development or progression of RA in patients with
very early disease was investigated in the Phase II,
exploratory, 2-year ADJUST trial [abatacept study to
determine the effectiveness in preventing the develop-
ment of RA in patients with undifferentiated inflammatory
arthritis (UA) (ADJUST) trial and to evaluate safety and
tolerability]. Following 6 months of DB, randomized (1:1)
treatment with either abatacept at the approved dose
(n=28) or placebo (n=28), abatacept treatment was
terminated. The proportion of patients who developed
RA according to ACR 1987 criteria [38] or discontinued
due to lack of efficacy at Year 1 was assessed.
Patients had a short disease duration (Table 1), and
although patients did not have RA according to ACR
1987 criteria, more than half already had evidence of
one or more erosion. As such it is likely that a significant
proportion had early RA. When abatacept was stopped at
Month 6, 22 and 17 patients treated with abatacept and
placebo, respectively, remained in the trial (i.e. had not
developed RA); by Year 2, 7 and 4 patients remained in
the trial. Numerically more placebo than abatacept pa-
tients developed RA over 1 year (66.7 vs 46.2%), although
CI overlapped. Radiographic assessments demonstrated
an inhibitory effect on structural damage progression at
Month 6, which was maintained for 6 months following
therapy cessation, with similar trends observed for MRI-
assessed osteitis, erosion and synovitis [24].
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Abatacept in RAEstablished disease
MTX-inadequate responders Phase IIb trial
The Phase IIb trial in MTX-inadequate responders was a
12-month, randomized (1 : 1 : 1) DB study designed to
evaluate the safety and efficacy of abatacept [2mg/kg
(n=105) or 10mg/kg (n=115)] plus MTX compared with
placebo plus MTX (n=119) [39]. The primary endpoint was
ACR20 response at Month 6. Patients completing the DB
period were eligible to enter an open-label long-term ex-
tension (LTE), in which all patients received abatacept
(approved dose). Results from the LTE have been pub-
lished up to 5 years [25], with experience reported up to
7 years [40].
Patients had high baseline disease activity (Table 1).
At Year 1, significantly greater improvements in RA signs
and symptoms (Table 2) and clinically meaningful
improvements in physical function were seen with abat-
acept 10mg/kg vs placebo [39]. The 2mg/kg dose
was considered suboptimal and was not pursued in
Phase III.
Over 12 months, serum levels of inflammatory biomark-
ers were significantly lower with abatacept 10mg/kg vs
placebo treatment, with numerical reductions in TNF-a
and RF also reported [41]. In particular, sIL-2R, IL-6,
soluble E-selectin and TNF-a were brought to within
the range considered normal.
Of the patients who entered the LTE, 59 and 52% re-
mained on treatment at Years 5 and 7, respectively, with
11.0% discontinuing due to lack of efficacy [25, 40].
Sustained efficacy improvements over 5 years were
observed in patients remaining on treatment (Fig. 2) [25].
Furthermore, low disease activity state (LDAS) and ACR70
were reported in 70 and 50% of patients at Year 7,
respectively [40]. Reductions in functional disability were
also maintained over 5 and 7 years [25, 40].
Abatacept in inadequate responders to MTX
The Phase III AIM trial included a similar patient popula-
tion of MTX-inadequate responders with established dis-
ease and high baseline disease activity (Table 1) [26, 42];
however, this trial also evaluated radiographic outcomes.
The design of this trial has been reported extensively [18,
42]. Here, patients received either abatacept (approved
dose; n=433) or placebo (n=219) on a background of
MTX for 1 year, after which patients who continued into
the LTE received open-label abatacept [26]. The
co-primary endpoints were ACR20 response, clinically
meaningful improvement in physical function and joint
damage progression as assessed by Genant-modified ES.
Approximately three-quarters of patients who entered
the LTE were still participating after 5 years, with
5.0% of discontinuations during the LTE due to lack of
efficacy and 8.7% to AEs [26]. Yearly discontinuations
were generally low (Years 2, 3, 4 and 5: 12.2, 6.3,
7.1 and 8.0%, respectively).
Through the 1-year DB period, improvements in clinical
efficacy and physical function were significantly greater
for abatacept vs placebo (Table 2; [42]). Post hoc analyses
demonstrated statistically significant improvements from
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Michael SchiffMonths 6 to 12 in the proportions of abatacept-treated
patients achieving ACR50 and ACR70 responses [42].
Throughout the open-label LTE, efficacy improvements
were maintained for patients who remained on treatment
[18, 26]. At Year 5, 33.7% of patients had achieved
DAS-28-defined remission, with 83.6, 61.1 and 39.6% of
patients achieving ACR20, ACR50 and ACR70 responses,
respectively [26]. Approximately three-quarters of patients
achieved clinically meaningful improvements in physical
function [improvement of 50.3 in HAQ-disability index
(HAQ-DI)] at Year 5 [26].
In post hoc, patient-level analyses from AIM, the major-
ity of patients maintained or improved their treatment re-
sponse or disease status from Months 3 to 12, suggesting
that patients who have not responded by Month 3 may
still achieve a clinically meaningful response over time
[43]. The sustainability of patient-level responses was
also evaluated for the LTE [44], revealing that the majority
of patients who had achieved LDAS, remission or normal-
ized physical function (i.e. HAQ-DI40.5) by Year 1
sustained these outcomes through 5 years.
At the end of the DB period, a significant inhibition of
structural damage progression was seen with abatacept
vs placebo, with 50% reduction in change from baseline
in Genant-modified Sharp scores compared with placebo
(Fig. 1B) [42]. Progressive reductions in changes from
baseline were observed in ES, joint-space narrowing
(JSN) score and TS over 5 years, for patients originally
randomized to abatacept, with progression reduced
by 50% in the second year relative to the first and
FIG.1Radiographic progression in early and established RA over 1 year of abatacept treatment. (A) Mean change from
baseline in TS, ES and JSN at Year 1 of the AGREE trial for abatacept plus MTX- and MTX alone-treated patients [23].
Adapted from Westhovens et al. [23] copyright 2009, with permission from the BMJ Publishing Group Ltd. (B) Mean
change from baseline in TS, ES and JSN at Year 1 of the AIM trial for abatacept- and placebo-treated patients [42]. ABA:
abatacept; PBO: placebo. Adapted from Kremer et al. [42].
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Abatacept in RAcontinued reductions in yearly progression up to Year 5.
A similar trend was also seen over 2 years in MTX-naı ¨ve
patients, in the AGREE trial [37]. Once the patients origin-
ally randomized to placebo had switched to abatacept,
annual mean changes progressively decreased in a similar
trend; however, differences in structural damage were still
seen between the groups at Year 5 [45]. Furthermore, ap-
proximately half of all patients treated with abatacept over
the entire study period exhibited no structural damage
progression (change in TS of 40) through 5 years.
Abatacept or infliximab versus placebo, a trial for
tolerability, efficacy and safety in treating RA
A third trial in MTX-inadequate responders provided the
opportunity to evaluate two biologics in a single study.
The placebo- and active-controlled ATTEST (abatacept
or infliximab versus placebo, a trial for tolerability, efficacy
and safety in treating RA) study, although not powered to
detect superiority, provided information on the relative
efficacy and safety profiles of abatacept and infliximab
vs placebo in the same population [46]. Patients with
an inadequate response to MTX were randomized
(3:3:2) to abatacept (approved dose, n=156), infliximab
(3mg/week, n=165) or placebo (n=110), with back-
ground MTX. At Month 6, patients in the placebo group
were switched to abatacept, and infliximab and abatacept
groups continued to Year 1, with blinding maintained.
The primary endpoint of this trial, reduction in DAS-28
(ESR) at Month 6 for abatacept vs placebo, was met, with
mean reductions of 2.53 vs 1.48 (P<0.001), respect-
ively. The proportion of patients achieving states of low
disease activity and DAS-28 remission was also greater
with abatacept (Table 2). Improvements in ACR20, ACR50
and ACR70 responses at Month 6 were significantly
greater vs placebo for both abatacept and infliximab.
The onset of ACR20 responses was generally more
rapid for infliximab than abatacept, but responses were
similar by Month 3. By Year 1, DAS-28 (ESR) reductions
of 2.88 and 2.25 were seen for abatacept- and
infliximab-treated patients, respectively, and ACR re-
sponses were maintained from Month 6 with abatacept
but not with infliximab treatment (Fig. 3) [46].
The ATTEST trial continued through 2 years; during the
second year of treatment, patients receiving infliximab
were switched to abatacept. Efficacy benefits observed
with abatacept in Year 1 were maintained through
2 years, as demonstrated by assessments of signs and
symptoms, physical function and disease activity [47]. In
patients who switched from infliximab to abatacept at
Year 1, efficacy benefits increased over the second year
and were similar to the original abatacept group by Year 2
[47]. In addition, a considerable proportion of infliximab
non-responders (i.e. ACR20 non-responders, or patients
with high disease activity state) who switched to abata-
cept after 1 year achieved improved clinical responses
with abatacept over the second year [48]. For patients
who had achieved LDAS or remission following 1 year of
infliximab, a high proportion were able to maintain these
disease states over Year 2.
TNF antagonist-inadequate responders abatacept trial in
treatment of anti-TNF inadequate responders
The efficacy of abatacept in patients with RA who have an
inadequate response to TNF antagonists was examined in
FIG.2Long-term clinical efficacy over 5 years of treatment with abatacept. The proportion of patients originally
randomized to the 10mg/kg abatacept group of the Phase IIb trial experiencing LDAS (DAS-28 CRP43.2) and
DAS-28-defined remission (DAS-28 CRP<2.6) by visit day. Responses are based on the intent-to-treat population for
patients with data available at the visit of interest (as-observed analysis). Broken line represents the DB period; data are
presented with 95% CIs. Reproduced from Westhovens et al. [25] with permission from the Journal of Rheumatology.
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Michael Schiffthe Phase III ATTAIN (abatacept trial in treatment of
anti-TNF inadequate responders) trial [49]. Patients had
an inadequate response to 53 months of treatment with
etanercept, infliximab or both. Patients were randomized
(2:1) to receive abatacept (n=258) or placebo (n=133),
plus one or more background DMARD, for the 6-month
DB period; patients entering the LTE received open-label
abatacept. The co-primary endpoints were ACR20 re-
sponse and improvement in physical function. Patients
had high baseline disease activity (Table 1). After 4
years of open-label therapy, approximately half of all pa-
tients who entered the LTE remained on treatment [50].
At the end of the 6-month DB period, improvements in
clinical efficacy and physical function were significantly
greater for abatacept vs placebo (Table 2). The proportion
of patients achieving improvements in ACR20, ACR50 and
ACR70 responses increased over 4.5 years of treatment
for patients who remained on treatment, as did the
proportions of patients achieving LDAS and remission
(18.3 vs 37.1% and 11.1 vs 25.7% at Month 6 vs Year
4.5, respectively), and clinically meaningful improvements
in physical function [50].
Abatacept researched in rheumatoid arthritis patients
with an inadequate anti-TNF response to validate
effectiveness
The second trial conducted in TNF-inadequate respond-
ers was a Phase IIIb/IV, 6-month, open-label study. The
ARRIVE (abatacept researched in rheumatoid arthritis
patients with an inadequate anti-TNF response to validate
effectiveness) trial was the first to assess the safety of
abatacept in patients who switched directly from TNF
antagonist therapy without undergoing washout [51].
This approach may be more clinically relevant for
day-to-day practice.
Patients in this trial had high levels of disease activity at
baseline (Table 1); overall, the inclusion criteria resulted in
a patient population that was more representative of clin-
ical practice than often included in randomized controlled
trials [51]: patients had an inadequate response to up to
three TNF antagonists that they could have failed for effi-
cacy, safety or tolerability reasons. Patients were eligible
even if they had a positive purified protein-derivative test
result. Abatacept could be administered as monotherapy
(USA only), and patients were not limited to a particular
background DMARD.
Similar, clinically meaningful, improvements were seen
in disease activity, physical function and health-related
quality of life, regardless of whether there was a washout
period or not. Post hoc analyses revealed that numerically
more patients who had previously failed one TNF antag-
onist achieved DAS-28-defined remission and LDAS than
those who had failed two or more [51].
Safety summary
Safety assessments from the trials discussed above have
demonstrated that the incidence of overall AEs and ser-
ious AEs (SAEs) was generally comparable for abatacept-
and placebo-treated patients [23, 24, 39, 42, 46, 49],
although in some trials the frequency of SAEs was re-
ported to be higher with abatacept [42]. The safety of
long-term abatacept treatment is reported to be consist-
ent, with the incidence of overall AEs and SAEs remaining
stable up to 7 years [40].
Events that are of significant interest to the treatment of
RA with biologic DMARDs, including serious infections,
malignancies and autoimmune events, were examined in
an integrated safety analysis that pooled data from the
Phase IIb, AIM, ATTAIN, ATTEST and ARRIVE studies
FIG.3Clinical efficacy over 1 year in the ATTEST trial. ACR responses achieved over Year 1 of the ATTEST trial. Data are
presented for the intent-to-treat population with a last observation carried forward analysis.
aInfliximab was administered
on Days 1, 15, 43, 85 and then every 56 days thereafter; abatacept dosing occurred at each visit day. Reproduced from
Schiff et al. [46] copyright 2008, with permission from the BMJ Publishing Group Ltd.
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Abatacept in RAoverviewed here, a Phase IIb study of abatacept 2mg/kg
in combination with etanercept [52], the Phase III ASSURE
(abatacept study of safety in use with other RA therapies)
study of abatacept with or without a biologic or non-
biologic DMARD [53], and a Phase II synovial biopsy
study [31], through December 2007. This included
4150 patients who were exposed to abatacept, represent-
ing 10365 patient-years of exposure, with an average
exposure period of 2.5 years [54–57].
Serious infections
In the integrated safety analysis, the incidence of serious
infections and related serious infections was generally
low, although it was higher for abatacept- compared
with placebo-treated patients over 1 year (serious infec-
tions: 3.47 vs 2.41 events/100 patient-years, respectively)
[54].
The incidence rates of serious infection and hospitalized
infection remained stable for the DB vs cumulative
periods, with 3.47 vs 2.98 serious infections, and 3.05 vs
2.73 hospitalized infections/100 patient-years, respective-
ly [54]. The risk for serious infections did not appear
to increase over time, as evidenced by incidence rates
at annual intervals (Table 3) [54]. The most common hos-
pitalized infections were pneumonia, bronchitis, cellulitis
and urinary tract infection [55]. There were few opportun-
istic infections observed, including Mycobacterium
tuberculosis (TB; 0.06 events/100 patient-years), aspergil-
losis (0.02), blastomycosis (0.01) and systemic candida
(0.01) [55].
Standardized incidence rates (SIRs) were calculated by
comparing the observed number of hospitalized infections
in the abatacept cumulative experience with that ex-
pected from external cohorts of RA patients treated with
non-biologic DMARDs [55]. Hospitalized infections were
not increased for abatacept-treated patients compared
with established RA patients [55].
Malignancies
As reported in the integrated safety analyses, the inci-
dence of malignancies [excluding non-melanoma skin
cancer (NMSC)] during DB treatment was reported to be
0.59 vs 0.63 events/100 patient-years for abatacept- vs
placebo-treated patients [56]. Incidence was generally
low and did not increase with increasing exposure (0.59
and 0.71/100 patient-years in the DB and cumulative per-
iods) [56]. Incidence of lung cancer and lymphoma, in par-
ticular, did not increase between the DB and cumulative
periods, with 0.24 and 0.16 lung cancers, and 0.06 and
0.07 lymphomas/100 patient-years, respectively [56].
Theincidenceofmalignancyintheabataceptclinicaltrial
programme, as assessed in the integrated safety analyses,
was compared with the incidence in five, observational
non-biologic DMARD-treated RA patient cohorts—the
British Columbia RA Cohort, the National Data Bank for
Rheumatic Diseases, the UK General Practice Research
Database, the UK Norfolk Arthritis Registry and the
Sweden Early Rheumatoid Arthritis Register Cohort [56].
The SIRs calculated suggested that the overall risk of
malignancy (excluding NMSC) was not significantly
increased in abatacept- compared with non-biologic
DMARD-treated patients; SIRs ranged from 0.40 to
1.06 for the cohorts. The risk of lung cancer did not
appear to be increased with abatacept (SIRs ranged from
0.65 to 1.84), and there appeared to be a comparable risk
for lymphoma (SIRs ranged from 0.60 to 1.23) [56].
Autoimmune events
During the integrated DB periods, autoimmune events
were reported in 28 (1.4%) abatacept- and 8 (0.8%)
placebo-treated patients; most events were mild or mod-
erate in intensity [57]. Incidence of autoimmune disorders
was generally low and did not increase with increasing
exposure to abatacept (1.43 and 1.59/100 patient-years
in the DB and cumulative periods, respectively) [57]. When
incidence was assessed at annual intervals, the rate
remained stable over time [57]. Psoriasis, the most
frequently reported autoimmune event, did not increase
between the DB and cumulative periods, with rates of
0.53 and 0.56 events/100 patient-years, respectively.
Abatacept has not been reported to lead to increased
formation of ANA and anti-dsDNA antibodies, compared
with placebo [33]. The integrated safety analyses support
this suggestion, reporting a lower proportion of abata-
cept- vs placebo-treated patients seroconverting to posi-
tive anti-ANA status and positive anti-dsDNA status over 6
and 12 months [58].
TABLE 3 Incidence of serious infections and autoimmune events in the integrated safety summary
a by annual intervals
[54, 57]
Events/100 patient-years (95% CI)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Total exposure, patient-years 3500 2400 1900 1500 700 180
All serious infections 3.68 (3.07, 4.37) 2.77 (2.14, 3.53) 2.41 (1.75, 3.23) 2.61 (1.84, 3.60) 2.16 (1.21, 3.57) 3.05 (0.99, 7.13)
Hospitalized infections
b 3.31 (2.73, 3.97) 2.55 (1.94, 3.28) 2.34 (1.70, 3.16) 2.46 (1.72, 3.42) 1.87 (1.00, 3.20) 3.02 (0.98, 7.06)
Autoimmune events 1.64 (1.25, 2.13) 2.02 (1.49, 2.68) 1.61 (1.09, 2.30) 1.25 (0.74, 1.97) 0.99 (0.40, 2.04) 0 (0, 1.99)
aData are for all those patients who received at least one dose of abatacept during the cumulative study period, for the eight
core abatacept trials.
bHospitalized infection is a subset of serious infection. Adapted from Smitten et al. [54] with permission
from BMJ Publishing Group Ltd, and Smitten et al. [57] with permission from the author.
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Michael SchiffSafety in ARRIVE
Comparable safety was seen in the ARRIVE trial (n=1046)
for both direct-switch and washout patients, with no in-
crease in the overall frequency of AEs seen between
groups either in the 6-month study period or monthly
after initiation of abatacept therapy [51]. In addition, no
cases of TB were reported, and no opportunistic infec-
tions occurred. Safety was also comparable regardless
of the number of prior TNF antagonists received [59].
Safety in ATTEST
The ATTEST trial examined the relative safety profiles of
two agents with differing mechanisms of action under the
same study conditions. Over 1 year of DB treatment, SAEs
(9.6 vs 18.2%), serious infections (1.9 vs 8.5%), acute
infusional events (7.1 vs 24.8%) and discontinuations
due to AEs (3.2 vs 7.3%) were less frequent in abatacept-
vs infliximab-treated patients [46]. Infections and infest-
ations were reported in 59.6 and 68.5%, and serious
infections in 1.9 and 8.5%, respectively. The most fre-
quently reported serious infection was pneumonia (1.3
and 1.8%, respectively). Five serious opportunistic infec-
tions were reported with infliximab treatment (herpetic en-
cephalitis, pseudomonas lung infection, peritoneal TB,
Pneumocystis jiroveci pneumonia and pulmonary TB); no
opportunistic infections were reported with abatacept.
Autoimmune events were uncommon in both groups (1.3
vs 0.6% for abatacept vs infliximab groups) [46].
Discussion and conclusions
The studies summarized here, encompassing up to
7 years of treatment, demonstrate that abatacept
provides clinically meaningful and sustained benefits
across multiple efficacy measures (signs and symptoms,
structural damage and physical function), without dose
adjustment, for patients with early, erosive disease who
are MTX naı ¨ve, and patients with established,
moderate-to-severe disease and an inadequate response
to MTX/DMARDs, or to TNF antagonists.
As with other biologics [60], abatacept demonstrates
statistical significance in achieving clinical efficacy
outcomes compared with placebo, over short-term, DB
treatment at the group level. Furthermore, the clinical
efficacy improvements seen with abatacept have been
observed at the individual patient level, with post hoc
analyses suggesting that patients responding to treatment
had a high probability of maintaining or further improving
responses over time. Sustained/improved long-term
effects were demonstrated with abatacept for signs and
symptoms, physical function and structural damage, with
data up to 7 years available in MTX-inadequate respond-
ers. Given that this type of sustained as opposed to inter-
mittent treatment response could have an impact on
long-term reduction of radiographic progression and
improvement in physical function, these data are of
particular interest, and evaluating this is strongly advised
by guidelines from EULAR and ACR [61].
Similarly to data for other biologics, the long-term effi-
cacy data for abatacept discussed here are based on
as-observed analyses, with no imputation rule for missing
data. In addition, some results are from post hoc assess-
ments, and data such as these should be interpreted with
caution. As-observed analyses are more vulnerable to the
discontinuation of patients, and may result in a perceived
increase in efficacy (as the proportion of responders is
calculated only from those patients still on treatment)
compared with the more conservative intent-to-treat
analysis. However, the trials discussed here report
relatively high patient retention with long-term treatment.
Furthermore, following only those patients who actually
remain on therapy may be more relevant over the long
term, given that the extrapolation of data over many
years from the start of a study is generally not recom-
mended. The data discussed here have been interpreted
with these concerns in mind.
Beneficial effects on radiographic progression have
been seen with abatacept plus MTX vs placebo plus
MTX, in patients with both early and long-standing RA.
Reductions in the annual rate of structural damage pro-
gression observed in both patient populations suggest
that abatacept has an increasing disease-modifying
effect on structural damage over time in the majority of
patients who respond. For patients with early RA treated
with MTX alone over 1 year, structural damage progres-
sion is reduced following the addition of abatacept; how-
ever, overall structural damage progression at Year 2
(after 1 year of abatacept treatment) remains greater for
these patients compared with patients who receive aba-
tacept from baseline. These findings suggest that delaying
biologic therapy in this population has a significant and
lasting impact on irreversible structural damage, and
support the earlier initiation of abatacept. In addition, find-
ings in patients with early erosive disease suggest that
earlier addition of abatacept to MTX provides clinically
meaningful benefits over delayed initiation in the preven-
tion of irreversible structural damage; when structural
damage progression was assessed in patients with very
early disease who were treated with abatacept for
6 months, the inhibitory effect was maintained for at
least 6 months following treatment cessation. These
data suggest that it may be possible to alter the progres-
sion of RA when abatacept is administered at a very early
stage in disease.
Clinical responses and radiographic benefits with
abatacept appear to be greater in MTX-naı ¨ve patients
compared with patients who have failed MTX or other
DMARDs. In addition, patients who previously failed
MTX treatment demonstrate higher clinical responses
than patients who have failed TNF antagonists. Although
abatacept provides considerable efficacy benefits irre-
spective of the number of previous TNF antagonists
received, there is a trend towards greater treatment re-
sponses in patients who have failed fewer agents, demon-
strating that the efficacy of abatacept can be optimized
when patients are switched through fewer prior TNF
antagonists.
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Abatacept in RATaken together, these results suggest that introducing
abatacept earlier in the treatment paradigm may lead to
more favourable results—a trend that has also been seen
with other biologic agents [19–22]. This shift towards ear-
lier, aggressive treatment in suitable patients will be
further facilitated by the recently published joint EULAR
and ACR guidelines for early RA [8].
Abatacept has demonstrated similar efficacy in patients
with early RA relative to other approved biologics [62]. A
meta-analysis in MTX-naı ¨ve patients with early disease
was conducted to assess clinical remission and radio-
graphic non-progression after 1 year of treatment with
abatacept, adalimumab, etanercept or infliximab, plus
MTX. Each of the biologics demonstrated favourable
results for inducing clinical remission and radiographic
non-progression compared with MTX monotherapy at
Year 1. Despite some limitations, these results provided
a broad view of the comparability of the efficacy of these
biologics [62]. Similar findings were reported in a
Cochrane Review meta-analysis of randomized, DB trials
of biologic DMARDs for RA treatment (abatacept, adali-
mumab, anakinra, etanercept, infliximab and rituximab),
which concluded that the different biologic agents
showed similar efficacy in patients with established RA,
with the exception of anakinra [63]. The observations
made in the Cochrane Review meta-analysis are sup-
ported by the findings from the ATTEST study, which pro-
vided a unique opportunity to evaluate two biologic
agents in a single study. Abatacept and infliximab demon-
strated comparable efficacy over 6 months of treatment in
MTX-inadequate responders. Furthermore, patients who
were switched from infliximab to abatacept treatment
at Year 1 maintained or improved their responses over
Year 2, suggesting that patients who achieve a good
response to infliximab but need to switch therapies, due
to safety concerns, for example, could expect to maintain
or improve their response with abatacept.
Long-term integrated safety data from up to eight
abatacept trials, representing >10000 patient-years of
exposure, confirm that, overall, abatacept has a favour-
able safety profile that is consistent with observations
from the short-term experience in all RA populations
studied, with no new clinically important safety issues
identified with long-term compared with short-term
findings. This is supported by a recent Cochrane Review
that reported the safety profile of abatacept to be
acceptable [60].
The increased risk of serious infections associated with
TNF antagonists has been well documented [64–68].
Serious infections, as reported in the integrated safety
analyses discussed here, are more frequent in abatacept-
compared with placebo-treated patients over 1 year
[54, 58]. However, the incidence rate of serious infections
with abatacept is at the lower end of the range observed
in RA patients treated with other biologics [69–71], and an
independent meta-analysis by Salliot et al. [72] reported
that this risk was not significantly increased with abata-
cept treatment compared with placebo. Importantly, the
incidence rate of serious infections is reported to remain
stable with increasing exposure to abatacept [54],
consistent with trends seen with anti-TNF agents.
Patients with RA may be at higher risk for lung cancer
and lymphoma than the general population [73, 74]; it is,
therefore, important to assess the incidence of malignan-
cies in patients treated with biologic agents. The risk for
malignancies, including lung cancer and lymphoma, re-
ported for abatacept in the integrated safety analyses
was generally low and comparable to that of the general
DMARD-treated RA population.
The Cochrane Review meta-analysis assessed safety
across the biologic DMARDs based on withdrawals from
clinical trials due to AEs [63]. Based on this criterion, there
was a trend towards a favourable safety profile of abata-
cept vs placebo, relative to adalimumab or infliximab [63].
In general, this is consistent with data from the ATTEST
trial in patients with an inadequate response to MTX,
which reported a higher frequency of SAEs and serious
infections (including opportunistic infections) with inflixi-
mab compared with abatacept.
Insummary,abataceptrepresentsaneffectivetreatment
option with an established safety profile in DMARD-naı ¨ve
patients with early disease, and in patients with RA who
have experienced an inadequate response to either non-
biologic or biologic DMARDs. Moving forwards, it will be of
interest to evaluate efficacy and safety outcomes with aba-
tacept treatment in clinical practice, as opposed to the
clinical trial settings discussed here. Further evaluation of
the efficacy and safety of abatacept in early and very early
disease will also be of high clinical importance, along with
investigation into the factors associated with response to
abatacept therapy.
Rheumatology key messages
. Abatacept represents an effective biologic treat-
ment with acceptable safety across the spectrum
of RA-patient populations.
. The risk–benefit profile of abatacept may be more
favourable when introduced earlier in the RA treat-
ment paradigm.
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